1. Multiple Sclerosis and suspected MS, 2. rare immunological or virus-associated encephalitides (NMOSD, MOG-, neuropil-, and others), 3. virus-associated CNS disorders such as progressive multifocal leukencephalopathy (PML), 4. inflammatory neuropathies (Guillain-Barré syndrome, CIDP, MMN, and others) and myopathies/myositides, 5. neurodegenerative diseases such as alzheimer's disease, spinal muscular atrophy, amyotrophic lateral sclerosis, amyloidoses, and others.
Conditions
Interventions
Group 1: Identification of biomarkers for inflammatory and degenerative diseases of the nervous system, by using patient samples stored in the study registry.
The identification of body fluid biomarke
Sponsors
Philipps Universität Marburg und Klinik für Neurologie, Universitätsklinikum Gießen & Marburg GmbH, Standort Marburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients undergoing clinical routine procedures at the Department of Neurology, University Hospital Marburg, may be recruited for this registry study. In particular, patients who suffer from the following conditions may participate: 1) Multiple Sclerosis (MS; suspected and/or confirmed diagnosis) 2) Rare immune- or virus-derived diseases of the central nervous system (CNS) with a MS-like course, such as - Neuromyelitis optica spectrum disorders (NMOSD; seropositive (AQP4-antibodies) or seronegative) - Autoantibody-derived encephalitides (incl. MOG-encephalomyelitis, neuropil-antibody-associated encephalitides) - CNS vasculitis and neurosarcoidosis 3) Virus-associated leukencephalopathies, specifically PML 4) Inflammatory neuropathies and myopathies/myositides, specifically Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Multifocal Motor Neuropathy (MMN), vasculitic neuropathies 5) Neurodegenerative diseases treated with modern (immuno-)therapies, amongst others Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS) and other motor neuron diseases (e.g. Spinal Muscular Atrophy (SMA)), amyloidoses and movement disorders. Additionally, all patients undergoing diagnostic blood or cerebrospinal fluid (CSF) assessment may participate in this study after signing the in-house "Broad Consent" patients consent form, and will be considered as suffering from "other neurological diseases (OND)".
Exclusion criteria
Exclusion criteria: - Patient age < 18 years - Denial of consent form signature / denial of study pariticpation / withdrawal of consent for study participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of body fluid biomarkers and/or (clinical-routine-obtained-)tissue samples to ameliorate the knowledge on pathogenesis, and to increase diagnostic and prognostic understanding of inflammatory and degenerative diseases of the nervous system. | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of subject demographic and clinical parameters with biomarker-associated datasets to ameliorate prognostic estimations in inflammatory and degenerative diseases of the nervous system. | — |
Countries
Germany
Contacts
Public ContactClemens Warnke
Philipps Universität Marburg und Klinik für Neurologie, Universitätsklinikum Gießen & Marburg GmbH, Standort Marburg
Outcome results
None listed